Pentixapharm's PENTIXAFOR Shows Promise in Non-Invasive Diagnosis of Primary Aldosteronism

Pentixapharm Holding AG has announced the publication of Phase 2 clinical data supporting the use of [68Ga]Ga-Pentixafor PET/CT for diagnosing primary aldosteronism. The study, published in the Journal of Nuclear Medicine, indicates that this non-invasive imaging tool is well tolerated and preferred by patients for identifying unilateral aldosterone-producing adenomas.

Conducted in Australia, the study compared [68Ga]Ga-Pentixafor PET/CT with the current invasive standard, adrenal vein sampling (AVS). Results suggest that the imaging tool offers high specificity and moderate sensitivity, potentially guiding surgical decisions in patients with hypertension due to primary aldosteronism.

Dr. Elisabeth Ng emphasized the method's advantage in pinpointing patients eligible for curative surgery, as well as its potential to replace AVS, making diagnostic procedures more accessible. Pentixapharm plans to advance to Phase 3 development as they engage with partners to enhance their clinical and commercial strategies.